(MDV) – StreetInsider.com Reports
-
Modiv (MDV) Misses Q4 EPS by 32c
-
Modiv (MDV) PT Raised to $18 at B.Riley
-
Modiv (MDV) Misses Q3 EPS by 72c
-
EF Hutton Assumes Modiv (MDV) at Buy
-
Modiv (MDV) Misses Q1 EPS by 44c
-
Modiv (MDV) PT Lowered to $17 at B.Riley
-
Modiv (MDV) PT Lowered to $19 at B.Riley
-
Modiv (MDV) repots Q3 results
-
UPDATE: Ladenburg Thalmann Starts Modiv (MDV) at Buy
-
Janney Starts Modiv (MDV) at Buy
-
Modiv (MDV) PT Lowered to $22 at B.Riley
-
Modiv (MDV) Reports Q2 EPS of $0.14
-
Colliers Securities Starts Modiv (MDV) at Buy
-
Modiv (MDV) Misses Q1 EPS by 147c
-
EF Hutton Starts Modiv (MDV) at Buy
-
Modiv (MDV) Files $200M Mixed Shelf
-
Modiv (MDV) PT Raised to $24 at B.Riley
-
Modiv (MDV) Announces $20 Million Share Repurchase Program and Declares Monthly Dividends for Common Shareholders
-
Modiv (MDV) Prices 40K Share Offering at $25/sh
-
Rodman & Renshaw downgrades Medivation, Inc. (MDV) to Market Perform
-
Rodman & Renshaw Starts Medivation (MED) at Market Outperform
-
Medivation (MDV) Said Medivation's Dimebon Meets All Five Efficacy Endpoint in Alzheimer's Study
Back to MDV Stock Lookup